Drug intelligence / Profile preview

NUPR1-shRNA lentiviral vector

Development stage
Unknown
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

NUPR1-shRNA lentiviral vector is a research-use-only gene silencing tool designed to knock down the expression of nuclear protein 1 (NUPR1), also known as p8 or candidate of metastasis 1. NUPR1 is a stress-inducible transcriptional cofactor that is overexpressed in various malignancies, including multiple myeloma, gastric cancer, hepatocellular carcinoma, and non-small cell lung cancer, where it promotes cell survival, proliferation, metastasis, and chemoresistance. The lentiviral vector delivers short hairpin RNA (shRNA) targeting NUPR1 mRNA, triggering RNA interference (RNAi) to degrade the transcript and downregulate NUPR1 protein levels. In preclinical studies, knockdown of NUPR1 using this vector has been shown to inhibit cell proliferation, induce G0/G1 cell cycle arrest, and promote apoptosis by downregulating Bcl-2 and PCNA, upregulating PTEN, and activating caspases.

Other names
NUPR1-shRNA lentivirusNUPR-1-shRNA lentivirusNUPR 1-shRNA lentiviruslentivirus-mediated NUPR1-shRNAshNUPR1 lentiviral vectorshNUPR-1 lentiviral vectorshNUPR 1 lentiviral vector
02

Targets

NUPR1 (Nuclear protein 1, transcriptional regulator)

Beyond the preview

Go deeper on NUPR1-shRNA lentiviral vector.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUPR1-shRNA lentiviral vector.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call